• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews

    7/17/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care
    Get the next $DXCM alert in real time by email
    • Dexcom's first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University's Shelomi Sanders
    • The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier this month

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250717183186/en/

    The 2025 Dexcom U roster consists of 21 athletes, with 13 new and eight returning team members, who all use Dexcom CGM to monitor their glucose levels and manage their diabetes.

    The 2025 Dexcom U roster consists of 21 athletes, with 13 new and eight returning team members, who all use Dexcom CGM to monitor their glucose levels and manage their diabetes.

    This year's Dexcom U roster welcomes 13 new athletes from colleges and universities across the country — including the University of Oregon, San Diego State University, and Northwestern University — representing 12 sports such as football, basketball, lacrosse, track & field, soccer, and more, alongside eight returning team members. The new athletes were selected following a dynamic, first-of-its-kind nationwide open call that drew over two hundred submissions, as Dexcom searched for the next great college athletes with diabetes to join the program.

    To officially welcome and celebrate the newly selected Dexcom U athletes, Dexcom hosted its Signing Day Camp earlier this month in Baltimore, Maryland. The event was hosted by Mark Andrews, Baltimore Ravens tight end and Dexcom Warrior, who relies on Dexcom G7 to manage his Type 1 diabetes and perform at the highest level. Mark was joined by Mike Golic Sr., NFL legend and sports broadcaster, who uses Stelo, Dexcom's over the counter glucose biosensor, to manage his Type 2 diabetes. The powerful, high-energy day brought together athletes with diabetes across all levels, including pro, college and youth sports, to redefine what's possible with diabetes. Both new and returning Dexcom U team members connected with Baltimore youth athletes and celebrated the resilience and determination that unite them.

    "It was incredibly inspiring to witness athletes of all ages come together at the Dexcom U Signing Day Camp to show what is possible while living with diabetes," said Mark Andrews, Dexcom Warrior and Baltimore Ravens tight end. "I know how impactful it would have been to have a support system like this in the early stages of my career, so for me, getting to be the role model I never had is really special."

    Dexcom U was created to elevate college athletes with diabetes who are breaking boundaries in sports and achieving their goals, despite their diagnosis. Since its inception in 2022, the program has directly impacted more than 40 college athletes across 38 schools and 19 sports. Each Dexcom U athlete relies on Dexcom continuous glucose monitoring (CGM) technology like Dexcom G7 to manage their diabetes with real-time data delivered directly to their smartphone or smartwatch,* empowering them to take control of their health and discover what they're made of.

    "This season, we set out to grow Dexcom U in ways that bring even more athletes into our Warrior community. From launching a new nationwide Open Call to hosting our first Dexcom U Signing Day Camp, we're creating impactful opportunities for athletes with diabetes to shine," said Leverne Marsh, executive vice president of marketing at Dexcom. "It's all part of our mission to show how Dexcom's continuous glucose monitoring technology supports performance, confidence, and connection."

    The 2025 Dexcom U roster consists of 21 athletes, with 13 new and eight returning team members, who all use Dexcom CGM to monitor their glucose levels and manage their diabetes:

    New athletes:

    • Ali Ramadan, Soccer, Creighton University
    • Anya Tribune, Soccer, Gardner-Webb University
    • Ari Long, Basketball, University of Oregon
    • Breanna Corral-Vargas, Acrobatics & Tumbling, Hawaii Pacific University
    • Clarke Byram, Track & Field, Pole Vault, University of Tennessee, Knoxville
    • Jackson Montgomery, Baseball, Coppin State University
    • Kya Epps, Track & Field, University of Cincinnati
    • Michael Trepeta, Lacrosse, Johns Hopkins University
    • Miles Byrd, Basketball, San Diego State University
    • Nadia Nemeth, Field Hockey, Northwestern University
    • Niamh Pfaff, Lacrosse, Yale University
    • Nikola Parichkov, Tennis, Wake Forest University
    • Patrick Heneghan, Football, Denison University

    Returning athletes:

    • Ben Mirisch, Water Polo, University of Southern California
    • Caleb Fauria, Football, University of Delaware
    • Isaac Traudt, Basketball, Creighton University
    • Jessica Walter, Softball, University of Connecticut
    • Madison Moraja, Track & Field, North Carolina State University
    • Nicholas Hahne, Cheerleading, University of Notre Dame
    • Raegan Lantz, Volleyball, Miami (OH) University
    • Shelomi Sanders, Basketball, Alabama A&M University

    Dexcom U athletes will receive access to Dexcom CGM, exclusive events and opportunities, and a supportive network of collegiate and professional athletes — including mentors like Seattle Sounders forward Jordan Morris and Dexcom U alum and Vegas Thrill setter Carly Graham — who support one another both on and off the field.

    To learn more about Dexcom U, visit www.Dexcom.com/DexcomU2025.

    About Dexcom

    Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

    Dexcom. Discover what you're made of. For more information, visit www.dexcom.com.

    *Smart device sold separately. For a list of compatible devices, visit www.Dexcom.com/compatibility.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250717183186/en/

    Media Contact

    Aly Brandt

    mediarelations@dexcom.com

    Investor Contact

    Sean Christensen

    sean.christensen@dexcom.com

    Get the next $DXCM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DXCM

    DatePrice TargetRatingAnalyst
    5/12/2026$77.00Buy
    The Benchmark Company
    3/24/2026$90.00In-line → Outperform
    Evercore ISI
    1/12/2026$71.00Equal Weight → Underweight
    Barclays
    12/2/2025$75.00Equal-Weight → Overweight
    Morgan Stanley
    11/25/2025$68.00In-line
    Evercore ISI
    10/21/2025$85.00Buy
    Stifel
    9/8/2025Outperform → Perform
    Oppenheimer
    8/21/2025$100.00Buy
    Argus
    More analyst ratings

    $DXCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

    Highly anticipated presentation of results from the CONNECT randomized control trial will be presented during the ADA Scientific Sessions conference on Saturday, June 6 at 1:45 p.m. CDT. Early access launch of a completely reimagined Stelo app will define a new era of glucose tracking for all people not on insulin seeking better health. Acquisition of Nutrisense will strengthen Dexcom's ability to provide personalized nutrition education and coaching to improve diabetes management and help further establish CGM as an effective tool for preventative care. DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforci

    6/4/26 9:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience

    Company establishes permanent council to drive ongoing innovation guided by community feedback Report outlines targeted commitments Dexcom is making to address sentiments shared by council members Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, healthcare professionals and community leaders, along with clear, actionable company commitments to further elevate product performance and user experience. Building on its position as the manufacturer of the most accurate CGM systems1, Dexcom continues to listen, innovate and act on customer insights to strengthen its techno

    6/2/26 9:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users

    Through ongoing quality and accounting reviews, Dexcom discovered two lots of scrapped product were stolen by a third party before destruction and sold into the market. Dexcom is working closely with the FDA and other authorities to ensure patient safety and to investigate the crime. DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties. Scrapping limited amounts of sensors that do not meet Dexcom standards is a routine

    5/26/26 9:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Altman Steven R was granted 5,565 shares (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    6/1/26 5:35:10 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    6/1/26 5:34:59 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    6/1/26 5:35:04 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Dexcom with a new price target

    The Benchmark Company initiated coverage of Dexcom with a rating of Buy and set a new price target of $77.00

    5/12/26 8:31:19 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Dexcom from In-line to Outperform and set a new price target of $90.00

    3/24/26 9:07:04 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom downgraded by Barclays with a new price target

    Barclays downgraded Dexcom from Equal Weight to Underweight and set a new price target of $71.00

    1/12/26 8:59:23 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    SEC Filings

    View All

    DexCom Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - DEXCOM INC (0001093557) (Filer)

    5/28/26 5:15:16 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by DexCom Inc.

    SD - DEXCOM INC (0001093557) (Filer)

    5/28/26 4:10:18 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by DexCom Inc.

    144 - DEXCOM INC (0001093557) (Subject)

    5/21/26 5:05:11 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Financials

    Live finance-specific insights

    View All

    Dexcom Reports First Quarter 2026 Financial Results

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended March 31, 2026. First Quarter 2026 Financial Highlights: Revenue grew 15% year-over-year to $1.192 billion on a reported basis and 12% year-over-year on an organic1 basis. U.S. revenue grew 11% and international revenue grew 26% on a reported basis and 17% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $255.3 million or 21.4% of revenue, an increase of 850 basis points compared to the first quarter of 2025. Non-GAAP operating income* of $264.4 million or 22.2% of reported revenue, an increase of 840 basis points compared to the first quarter of 2025. F

    4/30/26 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time

    DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, April 30, 2026. Management will hold a conference call to review the company's first quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the s

    4/2/26 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights: Revenue grew 13% year-over-year to $1.260 billion on a reported basis and 12% year-over-year on an organic1 basis. U.S. revenue grew 11% and international revenue grew 18% on a reported basis and 15% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $323.0 million or 25.6% of revenue, an increase of 860 basis points compared to the fourth quarter of 2024. Non-GAAP operating income* of $331.5 million or 26.3% of reported revenue, an increase of 750 basis points compared to the fourth

    2/12/26 4:03:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Leadership Updates

    Live Leadership Updates

    View All

    Dexcom Announces Governance Enhancements Ahead of 2026 Investor Day

    Will Add Two Independent Directors with MedTech and Operations Experience to be Named at a Later Date Reconstituted Operations and Innovation Committee Will Expand Mandate to Oversee Operations, Quality and Technical Roadmap Initiatives Follow Constructive Engagement with Elliott Management DexCom, Inc. (NASDAQ:DXCM) today announced key updates to its governance structure in conjunction with its upcoming 2026 Investor Day presentation that outlines a strategic and financial vision to best position the company for future growth. "We look forward to articulating our exciting vision for growth later today at Investor Day as we seek to empower greater metabolic health through our biosen

    5/14/26 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Appoints Rick Osterloh to Board of Directors

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Rick Osterloh to its Board of Directors, effective February 26, 2026. Mr. Osterloh is a highly accomplished technology executive with more than 20 years of leadership experience across consumer hardware, platform strategy and large-scale product operations. He currently serves as Senior Vice President, Platforms & Devices at Google, where he leads a unified group spanning the company's portfolio of advanced consumer technologies. This includes Android, Google Play, Chrome, and Google's Devices and Services Portfolio—Pixel phones, Google Nest smart home devices, and Fitbit wearables. Und

    2/26/26 4:15:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Appoints Euan Ashley to Board of Directors

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currently serves as Chair of the Department of Medicine at Stanford University, overseeing Stanford's largest department with 15 divisions and over 800 faculty. Dr. Ashley's research extends across precision medicine, data science, artificial intelligence, and digital health. He has also co-founded seven biotechnology companies and serves as the co-directo

    10/27/25 4:15:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/13/24 5:02:33 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/23 11:16:37 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/22 3:43:37 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care